Excellent presentation by Jens presenting results from KN866 trial that did not meet its primary endpoint in contrast with NIAGARA. Peri-op EV-pembro is the SOC in MIBC, awaiting V

Petros Grivas· @PGrivasMDPhD · X·2026-10-23 20:06· 2 天前评分70

正文 · 原文

Excellent presentation by Jens presenting results from KN866 trial that did not meet its primary endpoint in contrast with NIAGARA. Peri-op EV-pembro is the SOC in MIBC, awaiting VOLGA trial tomorrow! @myESMO #ESMO26 #ESMOAmbassadors @OncoAlert @Uromigos @shilpaonc @AndreaNecchi

661 浏览 · 21 赞 · 9 转发 · 0 回复

会议摘要

LBA2按 Presidential Symposium I 对上

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org

NCT04960709NCT04960709按 VOLGA 对上

VOLGA

https://esmocongress.esmo.org

引用@

Full house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space

在 X 查看被引用的帖子

来源：Petros Grivas · x.com